Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
🇺🇸 FDA

CagriSema News

🇺🇸 Americas ← All news

FDA CagriSema coverage for business development, investment, and market access teams

Latest on CagriSema

Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
NewsoncologyJun 7, 2026

Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst

Novo Nordisk’s CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This plan frames the results, the next clinical milestones, and why BD and investor teams should track them.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.